ArticleBMC biotechnology2002
Group I aptazymes as genetic regulatory switches.
Article in BMC biotechnology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 91 citations in OpenAlex.
- High-throughput engineering of ligand-activated splicing ribozyme through domain insertion.bioRxiv : the preprint server for biology · 2026Article
- Pairwise Engineering of Tandemly Aligned Self-Splicing Group I Introns for Analysis and Control of Their Alternative Splicing.Biomolecules · 2023Article
- Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study.Molecular diversity · 2022Article
- Supernova: A Deoxyribozyme that Catalyzes a Chemiluminescent Reaction.Angewandte Chemie (International ed. in English) · 2022Article
- Streamlined CRISPR genome engineering in wild-type bacteria using SIBR-Cas.Nucleic acids research · 2021Article
- Review
- The case of the missing allosteric ribozymes.Nature chemical biology · 2021Review
- Ligand-dependent tRNA processing by a rationally designed RNase P riboswitch.Nucleic acids research · 2021Article
- Imaginary Ribozymes.ACS chemical biology · 2020Article
- Expanding the toolbox of synthetic riboswitches with guanine-dependent aptazymes.Synthetic biology (Oxford, England) · 2019Article
- How to Train a Cell-Cutting-Edge Molecular Tools.Frontiers in chemistry · 2017Review
- Programmable Genome Editing Tools and their Regulation for Efficient Genome Engineering.Computational and structural biotechnology journal · 2017Review
- Synthetic biology to access and expand nature's chemical diversity.Nature reviews. Microbiology · 2016Review
- Aptamers as a novel tool for diagnostics and therapy.Investigational new drugs · 2015Review
- Computational analysis of riboswitch-based regulation.Biochimica et biophysica acta · 2014Review
- Nucleic acid aptamers: research tools in disease diagnostics and therapeutics.BioMed research international · 2014Review
- Regulatory RNAs: charming gene management styles for synthetic biology applications.RNA biology · 2013Review
- A novel dengue virus detection method that couples DNAzyme and gold nanoparticle approaches.Virology journal · 2013Article
- Microbial biosensors: engineered microorganisms as the sensing machinery.Sensors (Basel, Switzerland) · 2013Review
- De novo design of a synthetic riboswitch that regulates transcription termination.Nucleic acids research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAllosteric ribozymes (aptazymes) that have extraordinary activation parameters have been generated in vitro by design and selection. For example, hammerhead and ligase ribozymes that are activated by small organic effectors and protein effectors have been selected from random sequence pools appended to extant ribozymes. Many ribozymes, especially self-splicing introns, are known control gene regulation or viral replication in vivo. We attempted to generate Group I self-splicing introns that were activated by a small organic effector, theophylline, and to show that such Group I aptazymes could mediate theophylline-dependent splicing in vivo.
resultsBy appending aptamers to the Group I self-splicing intron, we have generated a Group I aptazyme whose in vivo splicing is controlled by exogenously added small molecules. Substantial differences in gene regulation could be observed with compounds that differed by as little as a single methyl group. The effector-specificity of the Group I aptazyme could be rationally engineered for new effector molecules.
conclusionGroup I aptazymes may find applications as genetic regulatory switches for generating conditional knockouts at the level of mRNA or for developing economically viable gene therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.